Exclusive: Cellares expands deal with Bristol Myers on CAR-T asset, eyes manufacturing expansion
Cellares has expanded its partnership deal with Bristol Myers Squibb to assist the Big Pharma in developing another unnamed CAR-T cell therapy via its cell therapy manufacturing platform, Cell Shuttle.
The South San Francisco company also has its eyes on long-term expansion, which includes new collaborations and new builds in US, Europe and Asia, CEO Fabian Gerlinghaus said. There’s been an “avalanche of interest” from pharma companies looking to partner, Gerlinghaus told Endpoints News in an interview.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.